GENOPOIETIC is the first French company to be authorized both as
Pharmaceutical and Cell therapy institution specializing in the development of
innovative anti-cancer treatments.
The company has developed and proposes
innovative technologies allowing clinical lots manufacturing of:
- Autologous anti-cancer vaccines,
- Cell therapy-based treatments,
- Gene therapy-based treatments,
- Monoclonal antibodies and recombinant proteins,
- Cell banking,
- Aseptic filling.
GENOPOIETIC is a wholly-owned subsidiary of
Avax Technologies Inc., in Philadelphia (PA, USA).
